T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi,Marcus Ballinger,Benjamin Lyons,Jean Charles Soria,Mizuki Nishino,Josep Tabernero,Thomas Powles,David Smith,Axel Hoos,Chris McKenna,Ulrich Beyer,Ina Rhee,Gregg Fine,Nathan Winslow,Daniel S. Chen,Jedd D. Wolchok +15 more
TL;DR: Evaluation of PFS and patterns of response and progression revealed that allowance for TL reversion from PD per imRECIST may better identify patients with OS benefit, and may inform additional modifications to radiographic criteria to better reflect efficacy with CIT agents.
Journal ArticleDOI
Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance
Christian Kollmannsberger,T. Tandstad,Philippe L. Bedard,Gabriella Cohn-Cedermark,Peter Chung,Michael A.S. Jewett,Thomas Powles,Padraig Warde,Siamak Daneshmand,Andrew Protheroe,Scott Tyldesley,Peter C. Black,Kim N. Chi,Alan I. So,M. J. Moore,Craig R. Nichols +15 more
TL;DR: Active surveillance for CSI testis cancer leads to excellent outcomes and the vast majority of relapses occur within 2 years of orchiectomy for CSI nonseminoma and within 3 years for CSI seminoma.
Journal ArticleDOI
Local treatments for metastases of renal cell carcinoma: a systematic review
Saeed Dabestani,Lorenzo Marconi,Fabian Hofmann,Fiona Stewart,Thomas B. Lam,Steven E. Canfield,Michael Staehler,Thomas Powles,Boerje Ljungberg,Axel Bex +9 more
TL;DR: It is suggested that patients treated with complete metastasectomy have better survival and symptom control (including pain relief in bone metastases) than those treated with either incomplete or no metastas surgery.
Journal ArticleDOI
Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy
Anja Lorch,Jörg Beyer,Caroline Bascoul-Mollevi,Andrew Kramar,Lawrence H. Einhorn,Andrea Necchi,Christophe Massard,De Giorgi U,Aude Flechon,Kim Margolin,Jean-Pierre Lotz,Germa Lluch,Thomas Powles,Christian K. Kollmannsberger +13 more
TL;DR: Prognostic variables are important in patients with GCT who experienced treatment failure with cisplatin-based first-line chemotherapy and can be used to construct a prognostic model to guide salvage strategies.
Journal ArticleDOI
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Robert J. Motzer,Paul B. Robbins,Thomas Powles,Laurence Albiges,John B. A. G. Haanen,James Larkin,Xinmeng Jasmine Mu,Keith A. Ching,Motohide Uemura,Sumanta K. Pal,Boris Alekseev,Gwenaelle Gravis,Matthew T. Campbell,Konstantin Penkov,Jae-Lyun Lee,Subramanian Hariharan,Xiao Wang,Weidong Zhang,Jing Wang,Aleksander Chudnovsky,Aleksander Chudnovsky,Alessandra di Pietro,Amber C Donahue,Toni K. Choueiri +23 more
TL;DR: Important biological features associated with differential PFS between the treatment arms are identified, including new immunomodulatory and angiogenesis gene expression signatures (GESs), previously undescribed mutational profiles and their corresponding GESs, and several HLA types.